Industry leaders laid out practical steps to scale autologous and other cell therapies, focusing on automation, closed‑process manufacturing and global networks to cut cost and increase reproducibility. Fabian Gerlinghaus of Cellares explained how modular automated platforms and standardized, closed systems can convert bespoke cell treatments into more manufacturable medicines. A parallel industry panel, “Commercializing Autologous Cell Therapy,” convened manufacturing experts—including Pascal Touchon and former FDA reviewers—to debate regulatory expectations, quality systems, and the commercial case for decentralized versus centralized production. Speakers stressed the need for robust CMC strategies, regulatory engagement on comparability, and workforce training. The briefings reflect a broader shift: as clinical demand for cell therapies grows, biomanufacturing capacity, operator training and supply‑chain standardization are becoming strategic bottlenecks. Companies that demonstrate scalable, validated manufacturing models may gain a competitive edge when moving therapies from trials to routine care.